Literature DB >> 26940899

Anti-H1N1 influenza effects and its possible mechanism of Huanglian Xiangru Decoction.

Qiao-Feng Wu1, Wen-Rui Zhu2, Yun-Liang Yan3, Xiao-Xia Zhang4, Ya-Qi Jiang5, Feng-Ling Zhang6.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Huangliang Xiangru Decoction (HXD), which is described in a famous TCM monograph "Book of Nanyang for Life Savin", is frequently used for treating cold in summer and summer heat-dampness. AIM OF THE STUDY: To date, no pharmacological study on the anti-H1N1 influenza properties of HXD has been reported. The aim of the present study was to evaluate the therapeutic action of HXD on HIN1-induced acute pulmonary inflammation and its anti-influenza mechanism focus to TLRs signal pathway in a mouse model.
MATERIALS AND METHODS: the mice were intranasally infected with influenza virus to induce viral pneumonia, and then treated with different doses of HXD. The Lung index and pathological changes in the lung tissue of mice were investigated to value the anti-influenza virus effect of HXD. The concentrations of cytokines (IL-2, IL-6, TNF-α and IFN-γ) and anti-oxidant factor (NO, SOD and GSH) in serum of mice were determined with ELISA. RT-PCR and Western blot were used to determine the mRNA and protein expression of TLR3, TLR7, MyD88,TRAF3 and NF-κB p65 in the lung tissues, which are the key targets of TLRs pathway.
RESULTS: Compared with the infection group, the lung index of mice in ribavirin group, HXD high dose group and HXD middle dose group were significantly decreased, the lung indexes of these groups were 10.36±1.14mg/g, 9.89±0.79mg/g, and 10.97±0.67mg/g. Moreover, pathological changes were remarkable alleviated. HXD can reduce the contents of IL-6, TNF-α and IFN-γ, NO, and increase the contents of IL-2, SOD, GSH in serum of infected-mice significantly. At the same time, HXD can reduce the mRNA and protein expression of TLR3, TLR7, MyD88,TRAF3 and NF-κB p65 in the lung tissues of infected-mice significantly.
CONCLUSIONS: HXD has significant effects on H1N1 influenza by a quantity-effect relationship, and plays its anti-influenza effect by enhancing the body's antioxidant capacity, regulating the body's immune function and the host's TLRs pathway.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anti-H1N1 influenza; Huanglian Xiangru Decoction; TLRs pathway.

Mesh:

Substances:

Year:  2016        PMID: 26940899     DOI: 10.1016/j.jep.2016.02.042

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Anti-Influenza Effect and Mechanisms of Lentinan in an ICR Mouse Model.

Authors:  Huan Cui; Cheng Zhang; Chunmao Zhang; Zhuming Cai; Ligong Chen; Zhaoliang Chen; Kui Zhao; Sina Qiao; Yingchun Wang; Lijia Meng; Shishan Dong; Juxiang Liu; Zhendong Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-05-20       Impact factor: 6.073

2.  Sheng Jiang San, a traditional multi-herb formulation, exerts anti-influenza effects in vitro and in vivo via neuraminidase inhibition and immune regulation.

Authors:  Tianbo Zhang; Mengjie Xiao; Chun-Kwok Wong; Ka-Pun Chris Mok; Xin Zhao; Huihui Ti; Pang-Chui Shaw
Journal:  BMC Complement Altern Med       Date:  2018-05-08       Impact factor: 3.659

3.  Chaiqin Qingning Capsule Inhibits Influenza Virus Infection and Inflammation In Vitro and In Vivo.

Authors:  Jin Zhao; Yanbing Hao; Xuanzi Xia; Runfeng Li; Xiaodong Huang; Zifeng Yang; Xinhua Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-11       Impact factor: 2.629

4.  Intestinal Flora: A Potential Mechanism by Which Yinlai Decoction Treats Lipopolysaccharide-Induced Pneumonia.

Authors:  Jingnan Xu; Xueyan Ma; Chen Bai; Xin Jiang; Ling Huang; Fei Gao; Yini Li; He Yu; Tiegang Liu; Xiaohong Gu
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-23       Impact factor: 2.629

5.  Preliminary study of Yinhuapinggan granule against H1N1 influenza virus infection in mice through inhibition of apoptosis.

Authors:  Hai-Xia Du; Hui-Fen Zhou; Jie-Hong Yang; Yi-Yu Lu; Yu He; Hai-Tong Wan
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.